Zansecimab Uses, Dosage, Side Effects and more
Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).
| Attribute | Details |
|---|---|
| Trade Name | Zansecimab |
| Generic | Zansecimab |
| Zansecimab Other Names | Zansecimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Zansecimab works
Zansecimab is a humanized IgG4 isotype antibody that neutralizes phospho-Tie2 induction due to Ang2, thereby stopping angiogenesis. The mechanism behind the neutralization is due to the antibody binding with high affinity to, and inhibiting Ang2.
